1. Pink Sheet
  2. >>Geography
  3. >>Europe

UK’s NICE Seeks Feedback On Proposed Improvements To Its Processes

 
• By Francesca Bruce

Proposals extend the health technology appraisal body's focus beyond final guidance to support for early development and real world performance.

Process Improvement on the Mechanism of Metal Gears
NICE Looks To the future • Source: Shutterstock

NICE, the health technology appraisal institute for England and Wales, has published proposals on how to improve the processes it uses when developing guidance on health technologies. The pharmaceutical industry has welcomed the opportunity to ensure more consistency and predictability when working with NICE.

The consultation comes as part of a wide-reaching and much anticipated review that aims to identify key areas for change...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By Dave Wallace

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

Report Shows Extent Of AI Use In EU Medicines Regulation During 2024

 
• By Eliza Slawther

The AI observatory, created by the European medicines regulatory network to track the evolving use of artificial intelligence in medicines development and regulation, has issued its first annual report.

‘Unprecedented Story’: Revoked EU Marketing Authorization Fails To Thwart Translarna Sales

 
• By Francesca Bruce

PTC Therapeutics is continuing to supply its Duchenne muscular dystrophy treatment, Translarna, in some European markets, despite EU revocation of the drug’s conditional marketing authorization earlier this year.

UK HRA Sets Targets For Digital Overhaul, Trial Transparency And Trust

 
• By Vibha Sharma

The UK Health Research Authority’s latest three-year strategy sets ambitious targets to make research more transparent. One World Health Organization official believes the authority can go further by setting equally high standards for the timely reporting of clinical trial results.

More from Geography